Haemonetics (HAE) Cash & Equivalents (2009 - 2026)

Haemonetics' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $245.4 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 19.99% year-over-year to $245.4 million in Q1 2026; TTM through Mar 2026 was $245.4 million, a 19.99% decrease from a year earlier, with the FY2026 full-year figure at $245.4 million, down 19.99% from the prior year.
• Cash & Equivalents eased to $245.4 million in Q1 2026 per HAE's latest filing, from $363.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $363.4 million in Q4 2025 and bottomed at $178.8 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $285.1 million (2023), against an average of $274.4 million.
• Across the five-year window, Cash & Equivalents tumbled 37.15% in 2024 and soared 71.57% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $224.0 million in 2022, then retreated by 13.4% to $194.0 million in 2023, then jumped by 65.4% to $320.8 million in 2024, then rose by 13.25% to $363.4 million in 2025, then sank by 32.45% to $245.4 million in 2026.
• Per Business Quant, the three latest HAE Cash & Equivalents figures stand at $245.4 million (Q1 2026), $363.4 million (Q4 2025), and $296.4 million (Q3 2025).